Safety and immune response test of a new meningitis B vaccine
Treatments studied
Part of Infections clinical trials.
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You have a body mass index between 18 and 32.
- You have not received a meningitis B vaccine before.
- You are in good general health without serious medical conditions.
- If female, you are not pregnant or breastfeeding and use effective birth control.
- You have not used certain medications like strong steroids or blood thinners recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different booster shots for meningitis B in young adults who already got the Bexsero vaccine at least 2.5 years ago. The goal is to see which booster works best to keep you protected.
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
This trial tests a new vaccine that helps protect against 6 types of meningococcal bacteria, which can cause serious infections like meningitis. It is for healthy people aged 2 to 59 years.
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
Hear when a new Neisseria Meningitidis Serogroup B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.